162 related articles for article (PubMed ID: 22023523)
1. Synergistic cytotoxicity of the DNA alkylating agent busulfan, nucleoside analogs and suberoylanilide hydroxamic acid in lymphoma cell lines.
Valdez BC; Murray D; Nieto Y; Li Y; Wang G; Champlin RE; Andersson BS
Leuk Lymphoma; 2012 May; 53(5):973-81. PubMed ID: 22023523
[TBL] [Abstract][Full Text] [Related]
2. Cladribine, gemcitabine, busulfan, and SAHA combination as a potential pretransplant conditioning regimen for lymphomas: A preclinical study.
Ji J; Valdez BC; Li Y; Liu Y; Teo EC; Nieto Y; Champlin RE; Andersson BS
Exp Hematol; 2016 Jun; 44(6):458-65. PubMed ID: 26976752
[TBL] [Abstract][Full Text] [Related]
3. The histone deacetylase inhibitor SAHA sensitizes acute myeloid leukemia cells to a combination of nucleoside analogs and the DNA-alkylating agent busulfan.
Song G; Valdez BC; Li Y; Dominguez JR; Corn P; Champlin RE; Andersson BS
Leuk Lymphoma; 2014 Jul; 55(7):1625-34. PubMed ID: 24144307
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic modifiers enhance the synergistic cytotoxicity of combined nucleoside analog-DNA alkylating agents in lymphoma cell lines.
Valdez BC; Nieto Y; Murray D; Li Y; Wang G; Champlin RE; Andersson BS
Exp Hematol; 2012 Oct; 40(10):800-10. PubMed ID: 22687754
[TBL] [Abstract][Full Text] [Related]
5. Synergistic cytotoxicity of sorafenib with busulfan and nucleoside analogs in human FMS-like tyrosine kinase 3 internal tandem duplications-positive acute myeloid leukemia cells.
Song G; Valdez BC; Li Y; Liu Y; Champlin RE; Andersson BS
Biol Blood Marrow Transplant; 2014 Nov; 20(11):1687-95. PubMed ID: 25111583
[TBL] [Abstract][Full Text] [Related]
6. The synergistic cytotoxicity of clofarabine, fludarabine and busulfan in AML cells involves ATM pathway activation and chromatin remodeling.
Valdez BC; Li Y; Murray D; Champlin RE; Andersson BS
Biochem Pharmacol; 2011 Jan; 81(2):222-32. PubMed ID: 20933509
[TBL] [Abstract][Full Text] [Related]
7. Clofarabine ± fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS.
Andersson BS; Valdez BC; de Lima M; Wang X; Thall PF; Worth LL; Popat U; Madden T; Hosing C; Alousi A; Rondon G; Kebriaei P; Shpall EJ; Jones RB; Champlin RE
Biol Blood Marrow Transplant; 2011 Jun; 17(6):893-900. PubMed ID: 20946966
[TBL] [Abstract][Full Text] [Related]
8. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y
J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the cytotoxicity of cladribine and clofarabine when combined with fludarabine and busulfan in AML cells: Enhancement of cytotoxicity with epigenetic modulators.
Valdez BC; Li Y; Murray D; Ji J; Liu Y; Popat U; Champlin RE; Andersson BS
Exp Hematol; 2015 Jun; 43(6):448-61.e2. PubMed ID: 25704054
[TBL] [Abstract][Full Text] [Related]
10. ABT199/venetoclax potentiates the cytotoxicity of alkylating agents and fludarabine in acute myeloid leukemia cells.
Valdez BC; Murray D; Yuan B; Nieto Y; Popat U; Andersson BS
Oncotarget; 2022; 13():319-330. PubMed ID: 35154579
[TBL] [Abstract][Full Text] [Related]
11. Romidepsin enhances the cytotoxicity of fludarabine, clofarabine and busulfan combination in malignant T-cells.
Valdez BC; Brammer JE; Li Y; Murray D; Teo EC; Liu Y; Hosing C; Nieto Y; Champlin RE; Andersson BS
Leuk Res; 2016 Aug; 47():100-8. PubMed ID: 27294334
[TBL] [Abstract][Full Text] [Related]
12. Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma.
Nieto Y; Valdez BC; Thall PF; Jones RB; Wei W; Myers A; Hosing C; Ahmed S; Popat U; Shpall EJ; Qazilbash M; Gulbis A; Anderlini P; Shah N; Bashir Q; Alousi A; Oki Y; Fanale M; Dabaja B; Pinnix C; Champlin R; Andersson BS
Cancer; 2016 Sep; 122(17):2680-8. PubMed ID: 27203405
[TBL] [Abstract][Full Text] [Related]
13. Synergistic Cytotoxic Effect of Busulfan and the PARP Inhibitor Veliparib in Myeloproliferative Neoplasms.
Patel PR; Senyuk V; Rodriguez NS; Oh AL; Bonetti E; Mahmud D; Barosi G; Mahmud N; Rondelli D
Biol Blood Marrow Transplant; 2019 May; 25(5):855-860. PubMed ID: 30615982
[TBL] [Abstract][Full Text] [Related]
14. The PARP inhibitor olaparib enhances the cytotoxicity of combined gemcitabine, busulfan and melphalan in lymphoma cells.
Valdez BC; Li Y; Murray D; Liu Y; Nieto Y; Champlin RE; Andersson BS
Leuk Lymphoma; 2017 Nov; 58(11):2705-2716. PubMed ID: 28394191
[TBL] [Abstract][Full Text] [Related]
15. Synergistic cytotoxicity of fludarabine, clofarabine, busulfan, vorinostat and olaparib in AML cells.
Valdez BC; Yuan B; Murray D; Ramdial JL; Nieto Y; Popat U; Tang X; Andersson BS
Front Oncol; 2023; 13():1287444. PubMed ID: 38074694
[TBL] [Abstract][Full Text] [Related]
16. Mechanistic studies on the synergistic cytotoxicity of the nucleoside analogs gemcitabine and clofarabine in multiple myeloma: relevance of p53 and its clinical implications.
Valdez BC; Wang G; Murray D; Nieto Y; Li Y; Shah J; Turturro F; Wang M; Weber DM; Champlin RE; Qazilbash MH; Andersson BS
Exp Hematol; 2013 Aug; 41(8):719-30. PubMed ID: 23648290
[TBL] [Abstract][Full Text] [Related]
17. Synergistic cytotoxicity of busulfan, melphalan, gemcitabine, panobinostat, and bortezomib in lymphoma cells.
Teo EC; Valdez BC; Ji J; Li Y; Liu Y; Brammer JE; Hosing C; Nieto Y; Champlin RE; Andersson BS
Leuk Lymphoma; 2016 Nov; 57(11):2644-52. PubMed ID: 26980288
[TBL] [Abstract][Full Text] [Related]
18. Differential effects of histone deacetylase inhibitors on cellular drug transporters and their implications for using epigenetic modifiers in combination chemotherapy.
Valdez BC; Li Y; Murray D; Brammer JE; Liu Y; Hosing C; Nieto Y; Champlin RE; Andersson BS
Oncotarget; 2016 Sep; 7(39):63829-63838. PubMed ID: 27564097
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic modification enhances the cytotoxicity of busulfan and4-hydroperoxycyclophosphamide in AML cells.
Valdez BC; Tang X; Li Y; Murray D; Liu Y; Popat U; Champlin RE; Andersson BS
Exp Hematol; 2018 Nov; 67():49-59.e1. PubMed ID: 30102945
[TBL] [Abstract][Full Text] [Related]
20. Long-Term Outcomes after Treatment with Clofarabine ± Fludarabine with Once-Daily Intravenous Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and Myelodysplastic Syndrome.
Alatrash G; Thall PF; Valdez BC; Fox PS; Ning J; Garber HR; Janbey S; Worth LL; Popat U; Hosing C; Alousi AM; Kebriaei P; Shpall EJ; Jones RB; de Lima M; Rondon G; Chen J; Champlin RE; Andersson BS
Biol Blood Marrow Transplant; 2016 Oct; 22(10):1792-1800. PubMed ID: 27377901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
